West Pharmaceutical Services (WST) Stock Forecast & Price Target

$335.56 +7.17 (+2.18%)

As of 01/3/2025 05:39 PM Eastern

West Pharmaceutical Services - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 5 Analyst Ratings

Sell
0

Hold
1

Buy
4

Based on 5 Wall Street analysts who have issued ratings for West Pharmaceutical Services in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 1 has given a hold rating, and 4 have given a buy rating for WST.

Consensus Price Target

$437.75
30.45% Upside

According to the 5 analysts' twelve-month price targets for West Pharmaceutical Services, the average price target is $437.75. The highest price target for WST is $536.00, while the lowest price target for WST is $355.00. The average price target represents a forecasted upside of 30.45% from the current price of $335.56.

Get the Latest News and Ratings for WST and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for West Pharmaceutical Services and its competitors.

WST Analyst Ratings Over Time

Type	Current Forecast 1/6/24 to 1/5/25	1 Month Ago 12/7/23 to 12/6/24	3 Months Ago 10/8/23 to 10/7/24	1 Year Ago 1/6/23 to 1/6/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$437.75	$460.33	$442.75	$381.25
Forecasted Upside	30.45% Upside	42.81% Upside	52.34% Upside	12.30% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

WST Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

WST Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

West Pharmaceutical Services Stock vs. The Competition

Type	West Pharmaceutical Services	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.82	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	30.45% Upside	23,653.83% Upside	14.54% Upside
News Sentiment Rating	Positive News See Recent WST News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/13/2024	Bank of America 3 of 5 stars		Boost Target	Buy ➝ Buy	$350.00 ➝ $355.00	+8.95%
12/13/2024	Wolfe Research 3 of 5 stars	D. Schenkel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
12/12/2024	UBS Group 4 of 5 stars	J. Sourbeer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$350.00 ➝ $390.00	+22.63%
2/13/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$440.00 ➝ $470.00	+15.58%
2/7/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$323.00 ➝ $536.00	+34.58%
10/27/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$420.00 ➝ $390.00	+20.06%
2/22/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$250.00 ➝ $290.00	-5.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:07 AM ET.

Should I Buy West Pharmaceutical Services Stock? WST Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, December 22, 2024. Please send any questions or comments about these West Pharmaceutical Services pros and cons to contact@marketbeat.com.

West Pharmaceutical Services
Bull Case

Here are some ways that investors could benefit from investing in West Pharmaceutical Services, Inc.:

West Pharmaceutical Services, Inc. reported earnings per share of $1.85 for the latest quarter, exceeding the consensus estimate of $1.50, indicating strong financial performance and effective management.
The company has increased its quarterly dividend from $0.20 to $0.21 per share, reflecting a commitment to returning value to shareholders and a healthy payout ratio of 12.46%.
With a current stock price of $330.05, West Pharmaceutical Services, Inc. is positioned well within its 52-week range, suggesting potential for growth as it approaches its one-year high of $413.70.
Analysts have a consensus rating of "Moderate Buy" for the stock, with a target price of $437.75, indicating optimism about the company's future performance.
The company has a strong return on equity of 18.41% and a net margin of 17.37%, showcasing its efficiency in generating profits relative to shareholder equity and overall revenue.

West Pharmaceutical Services
Bear Case

Investors should be bearish about investing in West Pharmaceutical Services, Inc. for these reasons:

The company's revenue for the latest quarter was down 0.1% year-over-year, which may indicate challenges in maintaining growth in a competitive market.
Despite the recent increase in dividends, the yield remains relatively low at 0.25%, which may not attract income-focused investors looking for higher returns.
West Pharmaceutical Services, Inc. has a high P/E ratio of 48.97, suggesting that the stock may be overvalued compared to its earnings, which could deter value investors.
Insider ownership is only 0.53%, which may raise concerns about alignment between management and shareholder interests.
The stock has experienced volatility, with a beta of 1.01, indicating that it may move in line with the market, which could pose risks during market downturns.

WST Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for West Pharmaceutical Services is $437.75, with a high forecast of $536.00 and a low forecast of $355.00.
: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There is currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" WST shares.
: According to analysts, West Pharmaceutical Services's stock has a predicted upside of 30.45% based on their 12-month stock forecasts.
: Over the previous 90 days, West Pharmaceutical Services's stock had 1 upgrade by analysts.
: West Pharmaceutical Services has been rated by research analysts at Bank of America, UBS Group, and Wolfe Research in the past 90 days.
: Analysts like West Pharmaceutical Services less than other "medical" companies. The consensus rating score for West Pharmaceutical Services is 2.80 while the average consensus rating score for "medical" companies is 2.82. Learn more on how WST compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NYSE:WST) was last updated on 1/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

West Pharmaceutical Services (WST) Stock Forecast & Price Target